BI 6727

DRUG7 trials

Sponsors

Boehringer Ingelheim

Conditions

Carcinoma, Non-Small-Cell LungNeoplasmsOvarian Neoplasms

Phase 1

Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers

CompletedNCT00969553

Boehringer IngelheimNeoplasms

Start: 2009-08-31End: 2011-09-30Updated: 2019-07-26

BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour

CompletedNCT00969761

Boehringer IngelheimNeoplasms

Start: 2009-08-31End: 2012-02-29Updated: 2019-01-31

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

CompletedNCT01022853

Boehringer IngelheimNeoplasms

Start: 2009-12-31End: 2013-02-28Updated: 2018-07-30

BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours

CompletedNCT01145885

Boehringer IngelheimNeoplasms

Start: 2010-06-30End: 2010-11-30Updated: 2019-01-31

BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours

CompletedNCT02273388

Boehringer IngelheimNeoplasms

Start: 2005-11-04End: 2021-04-06Updated: 2023-10-03

Phase 2

Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC

CompletedNCT00824408

Boehringer IngelheimCarcinoma, Non-Small-Cell Lung

Start: 2009-03-31End: 2015-08-31Updated: 2016-09-20

BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer

CompletedNCT01121406

Boehringer IngelheimOvarian Neoplasms

Start: 2010-04-30End: 2014-06-30Updated: 2015-08-13

Related Papers

A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.

2015-09-2239 citations

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.

2015-03-2230 citations